Knight Therapeutics Inc banner

Intrinsic Value

The intrinsic value of Knight Therapeutics Inc (GUD) under the Base Case is 9.08 CAD per share. Compared with the current market price of 11.92 CAD, the stock appears Overvalued by 24% .

The intrinsic value is calculated using the DCF method. Net margin recovers from -1.2% last year to 9% by 2033. If net margin stayed at its five-year average of -1.8%, the estimate would be about CA$6.12. The value of the years after 2033 is tied to revenue, so margins count only until then.

Do our valuations actually work? See backtest results .

GUD Intrinsic Value
CA$9.08
Overvaluation 24%
Intrinsic Value
Price CA$11.92
Alert me when GUD is below its intrinsic value
Today CA$7.26 · 39.1% below the current price

GUD is more expensive than usual. It was this expensive or more expensive on just 22% of days in the past 5 years.

Alternatives to GUD

Fundamental Analysis

What Knight Therapeutics Does

Pharmaceuticals Health Care

Knight Therapeutics Inc. is a specialty pharmaceutical company that buys, licenses, and sells prescription medicines and hospital products. It does not usually discover drugs itself; instead, it focuses on bringing approved products from other companies into the markets where it has distribution and marketing rights. Its portfolio includes medicines for areas like oncology, infectious disease, and other specialty care settings.

Headquarters
Canada CA
Employees
830
IPO date
Feb 28, 2014
Read the full company overview
View Company Overview
Financials
Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Continue GUD Research

Decided on Knight Therapeutics? Get an email when GUD reaches the price you’d buy at. Free with an account.

Other Knight Therapeutics listings

What is the Intrinsic Value of one GUD stock?

The intrinsic value for Knight Therapeutics Inc (GUD) under the Base Case is 9.08 CAD.

Is GUD stock undervalued or overvalued?

Compared with the current market price of 11.92 CAD, the stock appears Overvalued by 24% .

How reliable are our estimates? See how past valuations played out
Back to Top